Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Seres Therapeutics (MCRB) Misses Q1 EPS by 8c, Revenues Miss
May 4, 2021 7:24 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.39), $0.08 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $5.72 million versus the consensus estimate of $6.45 million.
We continue to make steady progress across our broad microbiome pipeline and we look... More
